Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

Daily Assessment of Pain in Adults with Sickle Cell Disease

(2013) Wally R. Smith et al.   ANNALS OF INTERNAL MEDICINE

Nontransferrin-bound iron in transfused patients with sickle cell disease

(2010) A. INATI et al.   International Journal of Laboratory Hematology

Iron Metabolism and Iron Chelation in Sickle Cell Disease

(2009) Patrick B. Walter et al.   ACTA HAEMATOLOGICA

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

(2009) Ali Taher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

(2009) M. D. Cappellini et al.   HAEMATOLOGICA

Pathophysiology of Transfusional Iron Overload: Contrasting Patterns in Thalassemia Major and Sickle Cell Disease

(2009) John B. Porter   HEMOGLOBIN

Hepatic Iron Overload in Children With Sickle Cell Anemia on Chronic Transfusion Therapy

(2009) Kathy Brown et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Effect of transfusional iron intake on response to chelation therapy in -thalassemia major

(2007) A. R. Cohen et al.   BLOOD

Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels

(2007) Lina B. Karam et al.   PEDIATRIC BLOOD & CANCER